The estimated Net Worth of Thomas F Jr Kearns is at least 1.3 百万$ dollars as of 15 September 2021. Mr. Kearns owns over 13,100 units of FibroGen Inc stock worth over 15,906$ and over the last 10 years he sold FGEN stock worth over 835,524$. In addition, he makes 452,630$ as Lead Independent Director at FibroGen Inc.
Sign up
Mr. Kearns FGEN stock SEC Form 4 insiders trading
Thomas has made over 12 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 13,100 units of FGEN stock worth 151,698$ on 15 September 2021.
The largest trade he's ever made was exercising 18,000 units of FibroGen Inc stock on 11 March 2021 worth over 63,000$. On average, Thomas trades about 8,204 units every 108 days since 2014. As of 15 September 2021 he still owns at least 39,764 units of FibroGen Inc stock.
You can see the complete history of Mr. Kearns stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Kearns biography
Thomas F. Kearns Jr. serves as Lead Independent Director of the Company. Mr. Kearns has served on our board of directors since November 1996 and as lead independent director since June 7, 2017. Mr. Kearns is a retired partner of The Bear Stearns Companies Inc., an investment banking firm, where he was an investment banker in the healthcare area from 1974 until 1987. Prior to his career at Bear Stearns, Mr. Kearns worked for Merrill Lynch, an investment banking firm, from January 1959 until August 1969. Mr. Kearns was a trustee of the University of North Carolina Foundation and Endowment Fund for 16 years, he served on the board of directors of Biomet, Inc. from January 1980 until May 2005, and he served on the board of directors of Franklin Street Partners from 2013 until 2018. He received his Bachelor of Arts degree in History from the University of North Carolina.
What is the salary of Thomas Kearns?
As the Lead Independent Director of FibroGen Inc, the total compensation of Thomas Kearns at FibroGen Inc is 452,630$. There are 11 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of 5,856,450$.
How old is Thomas Kearns?
Thomas Kearns is 83, he's been the Lead Independent Director of FibroGen Inc since 2017. There are no older and 22 younger executives at FibroGen Inc.
What's Thomas Kearns's mailing address?
Thomas's mailing address filed with the SEC is 409 Illinois St, San Francisco, CA 94158, USA.
Insiders trading at FibroGen Inc
Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B Riggs、Thomas B Neff、Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.
What does FibroGen Inc do?
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
What does FibroGen Inc's logo look like?
Complete history of Mr. Kearns stock trades at FibroGen Inc
FibroGen Inc executives and stock owners
FibroGen Inc executives and other stock owners filed with the SEC include:
-
Kin-Hung Yu,
Chief Medical Officer -
James Schoeneck,
Chairman of the Board -
Elias Kouchakji,
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance -
Christine Chung,
Senior Vice President, China Operations -
Pat Cotroneo,
Chief Financial Officer -
Enrique A. Conterno,
CEO & Director -
Dr. Elias Kouchakji,
Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance -
Pat Cotroneo,
Exec. Advisor to CEO -
Suzanne Blaug,
Independent Director -
Thane Wettig,
Chief Commercial Officer -
Dr. Mark Eisner M.D., M.P.H.,
Chief Medical Officer -
Thomas Kearns,
Lead Independent Director -
Jeffrey Edwards,
Independent Director -
Rory Riggs,
Independent Director -
Gerald Lema,
Independent Director -
Jeffrey Henderson,
Independent Director -
Maykin Ho,
Independent Director -
Kalevi Kurkijarvi,
Independent Director -
Toshinari Tamura,
Independent Director -
James A. Schoeneck,
Chairman -
Benjamin Cravatt,
Director -
Aoife Brennan,
Director -
Thane Wettig,
Chief Commercial Officer -
Percy Carter,
Chief Scientific Officer -
Enrique Conterno,
Chief Executive Officer, Director -
Dr. John J. Hunter Ph.D.,
Chief Scientific Officer -
Dr. Michael J. Martinelli,
Sr. VP of Technical Devel. -
Juan Graham,
Chief Financial Officer -
Dr. Barry A. Berkowitz Ph.D.,
Founder -
Jorma Routti,
Director -
K Peony Yu,
Chief Medical Officer -
Thomas B Neff,
Chief Executive Officer -
Mark Eisner,
EVP, Chief Medical Officer -
Julian N Stern,
Director -
Frank H Md Valone,
Chief Medical Officer -
Miguel Madero,
Director -
Pharma Inc. Astellas,
-
Juan Graham,
CHIEF FINANCIAL OFFICER -
Deyaa Adib,
Chief Medical Officer